| Patients’ characteristics |
N (%) |
| On antiretroviral treatment at diagnosis |
36 (70.6%) |
| CD4 count (cells/ml) |
|
| <200 |
2 (3.9%) |
| 200-349 |
8 (15.7%) |
| 350-499 |
10 (19.6%) |
| ≥ 500 |
31 (60.8%) |
| Nadir CD4 count (cells/ml) |
|
| <200 |
16 (31.4%) |
| 200-349 |
9 (17.6%) |
| 350-499 |
10 (19.6%) |
| ≥ 500 |
16 (31.4%) |
| HIV RNA viral load (copies/ml) |
|
| Undetectable (≤ 75) |
32 (62.8%) |
| Detectable (>75) |
18 (35.3%) |
| Syphilis diagnosis |
|
| Asymptomatic seroconversion |
18 (35.3%) |
| Primary syphilis |
6 (11.8%) |
| Secondary syphilis |
17 (33.3%) |
| Neuro- or ocular syphilis |
7 (13.7%) |
| Unknown |
3 (5.9%) |
| RPR value |
|
| <16 |
13 (25.5%) |
| 16-32 |
12 (23.5%) |
| 64-128 |
20 (39.2%) |
| >128 |
6 (11.8%) |
| Syphilis treatment |
|
| Benzathine penicillin one dose |
15 (29.4%) |
| Benzathine penicillin three doses |
23 (45.1%) |
| IV penicillin G |
4 (7.8%) |
| Other |
9 (17.6%) |
| Patients’ treatment outcome (N=45) |
|
| Cured, no sequelae |
37 (82.2%) |
| Cured, with sequelae |
4 (8.9%) |
| Uncertain |
4 (8.9%) |
Abbreviations: HIV: Human Immunodeficiency Virus; CD4: Cluster of Differentiation 4;
RNA: Ribonucleic Acid; IV: Intravenous.